Management and prognosis of multiple sclerosis

British Journal of Hospital Medicine

Volumn 72, Issue 11 SUPPL., 2011, Pages

  Hassan Smith, Ghaniah ^a   Douglas, Michael R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80955140416     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2011.72.sup11.m174     Document Type: Article

References (13)

1. Association of British Neurologists (2009) Revised (2009) Association of British Neurologists' guidelines for prescribing in multiple sclerosis. www.abn.org.uk/abn/userfiles/file/ABN-MS-Guidelines-2009-Final(1).pdf (accessed 20 October 2011)
2. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329(24): 1764-9 (Pubitemid 23355549)
3. Comi G, Filippi M, Barkhof F et al; Early Treatment of Multiple Sclerosis Study Group (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268): 1576-82 (Pubitemid 32488815)
4. Ebers GC, Traboulsee A, Li D et al; Investigators of the 16-year Long-Term Follow-Up Study (2010) Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 81(8): 907-12
5. Fisniku LK, Brex PA, Altmann DR et al (2008) Disability and T2 MRI lesions: a 20-year followup of patients with relapse onset of multiple sclerosis. Brain 131(Pt 3): 808-17 (Pubitemid 351294716)
6. Freedman MS (2011) Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology 76(Suppl 1): S26-34
7. Hassan-Smith G, Douglas MR (2011) Epidemiology and diagnosis of multiple sclerosis: a practical approach. Br J Hosp Med 72(10): M146-51
8. IFNB Multiple Sclerosis Study Group (1993) Interferon [beta]-1b is effective in relapsingremitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 43: 655-61
9. Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343(13): 898-904
10. Khatri B, Barkhof F, Comi G et al (2011) Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 10: 520-9
11. Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA (2011) Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther 5: 255-74
12. O'Connor PW (2004) Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62(11): 2038-43 (Pubitemid 38738218)
13. PRISMS Study Group (1998) Randomised doubleblind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-504